Page last updated: 2024-09-03

caprylates and Parkinsonian Disorders

caprylates has been researched along with Parkinsonian Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Araki, T; Imai, Y; Itoyama, Y; Kato, H; Takahashi, A	1

Other Studies

1 other study(ies) available for caprylates and Parkinsonian Disorders

Article	Year
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease. Journal of the neurological sciences, 2003, Apr-15, Volume: 208, Issue:1-2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase	2003

Article

Year

Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.

Journal of the neurological sciences, 2003, Apr-15, Volume: 208, Issue:1-2

Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

2003